Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 4Myeloproliferative Disorders 3Leukemia, Myeloid, Chronic-Phase 3Neoplasms by Histologic Type 2Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid 2Hematologic Diseases 2Bone Marrow Diseases 2Blast Crisis 2Thyroid Neoplasms 1Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphatic Diseases 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

Rituximab 4Cyclophosphamide 4Etoposide 3Dexamethasone 3ponatinib 2pomalidomide 2fludarabine 2Whole-Body Irradiation 2Vincristine 2Sirolimus 2Prednisone 2Platelet Transfusion 2Mycophenolic Acid 2Lenalidomide 2Ifosfamide 2Doxorubicin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2Alemtuzumab 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2ricolinostat 1pembrolizumab 1nilotinib 1ibrutinib 1fludarabine phosphate 1epratuzumab 1daratumumab 1dacetuzumab 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Hematologic Diseases × ponatinib × Clear all
NCT02627677 2021-11-26

OPTIC-2L

Takeda

Phase 3 Terminated
44 enrolled 22 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡